These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 26646305)

  • 1. Subgroup mixable inference on treatment efficacy in mixture populations, with an application to time-to-event outcomes.
    Ding Y; Lin HM; Hsu JC
    Stat Med; 2016 May; 35(10):1580-94. PubMed ID: 26646305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correct and logical inference on efficacy in subgroups and their mixture for binary outcomes.
    Lin HM; Xu H; Ding Y; Hsu JC
    Biom J; 2019 Jan; 61(1):8-26. PubMed ID: 30353566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials.
    Liu Y; Wang B; Yang M; Hui J; Xu H; Kil S; Hsu JC
    Biom J; 2022 Feb; 64(2):198-224. PubMed ID: 35152457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing.
    Wei Y; Hsu JC; Chen W; Chew EY; Ding Y
    Stat Med; 2021 Dec; 40(29):6523-6540. PubMed ID: 34542190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials.
    Liu Y; Wang B; Tian H; Hsu JC
    Biom J; 2022 Feb; 64(2):246-255. PubMed ID: 34270810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliably basing conclusions on subgroups of randomized clinical trials.
    Koch A; Framke T
    J Biopharm Stat; 2014; 24(1):42-57. PubMed ID: 24392977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
    Zhang S; Liang F; Li W; Hu X
    J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using routine data to complement and enhance the results of randomised controlled trials.
    Lewsey JD; Leyland AH; Murray GD; Boddy FA
    Health Technol Assess; 2000; 4(22):1-55. PubMed ID: 11074392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
    Choi L; Dominici F; Zeger SL; Ouyang P
    Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discussion on "Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials" by Yi Liu, Bushi Wang, Miao Yang, Jianan Hui, Heng Xu, Siyoen Kil, and Jason C. Hsu.
    Pennello G; Xu D
    Biom J; 2022 Feb; 64(2):225-234. PubMed ID: 33377537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing causal relationships between treatments and clinical outcomes: always read the fine print.
    Freidlin B; Korn EL
    Bone Marrow Transplant; 2012 May; 47(5):626-32. PubMed ID: 21625225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trials, statistics, and clinical inference.
    Stone GW; Pocock SJ
    J Am Coll Cardiol; 2010 Feb; 55(5):428-31. PubMed ID: 20117455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group sequential enrichment design incorporating subgroup selection.
    Magnusson BP; Turnbull BW
    Stat Med; 2013 Jul; 32(16):2695-714. PubMed ID: 23315698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.